The article focuses on how financial pressures morphed biotechnology companies into specialty pharmaceutical manufacturers in the U.S. Investors and handlers of these companies are reluctant on investing new technologies. The author asserts that biotech investing is most suited to sophisticated investors capable of evaluating new technologies and understanding nontraditional metrics.